RT Journal Article
T1 Baseline description of the Spanish Academy of Dermatology infantile haemangioma nationwide prospective cohort. Comparison of patients treated with propranolol in routine clinical practice with previous pivotal clinical trial data.
T2 Descripción basal de la cohorte prospectiva de hemangioma infantil a nivel nacional de la Asociación Española de Dermatología. Comparación de los pacientes tratados con propranolol en la práctica clínica rutinaria y los datos de un ensayo clínico pivotal previo.
A1 Cuenca-Barrales, C
A1 Baselga-Torres, E
A1 Del Boz-González, J
A1 Vicente, A
A1 Palencia-Pérez, S I
A1 Campos-Domínguez, M
A1 Valdivieso-Ramos, M
A1 Martín-Santiago, A
A1 Montserrat-García, M T
A1 Azón-Masoliver, A
A1 Feito-Rodríguez, M
A1 Domínguez-Cruz, J J
A1 Roé-Crespo, E
A1 Salas-Márquez, C
A1 Giacaman, A
A1 Lorente-Lavirgen, A I
A1 Quintana-Castanedo, L
A1 de Vega-Martínez, M
A1 García-Doval, I
A1 Bernabéu-Wittel, J
K1 Capilar
K1 Capillary
K1 Cross-Sectional Studies
K1 Estudios prospectivos
K1 Estudios transversales
K1 Haemangioma
K1 Hemangioma
K1 Propranolol
K1 Prospective Studies
K1 Timolol
AB There are several therapeutic options for infantile haemangiomas (IH). Propranolol is used according to a pivotal trial. We aimed to describe the characteristics of IH in clinical practice, including the therapies used, and to compare the characteristics of patients treated with propranolol with those of the trial to assess its external validity. Consecutive patients attending 12 Spanish hospitals from June 2016 to October 2019 were included (n=601). The mean age was 3.9 (SD:1.9) months, with a 2:1 female-to-male ratio. Most IHs were localized (82%, 495), superficial (64%, 383) and located in the face (25%, 157) and trunk (31%, 188). Median size was 17 (IR: 10-30) x 12 (IR: 7-20) mm. Complications were found in 16 (3%) patients. Treatment was initiated for 52% (311). Most patients received timolol (76%, 237); propranolol was reserved for complications or high-risk IHs. Aesthetic impairment was the main reason for starting therapy (64%, 199). Several characteristics of the patients and IHs treated with propranolol are similar to those of the pivotal clinical trial, but 1/3 of IHs did not reach the minimum diameter to meet the inclusion criteria, and important prognostic information was not reported. As most patients receive treatment for aesthetic impairment, there is a need to better understand the aesthetic results of therapies and to increase evidence on the use of timolol, which is currently the most common therapy. Propranolol is being used in a population generally similar to that of the trial; however, this statement cannot be definitely confirmed.
YR 2021
FD 2021-05-27
LK https://hdl.handle.net/10668/26365
UL https://hdl.handle.net/10668/26365
LA en
LA es
DS RISalud
RD Apr 6, 2025